$Nanobiotix (NBTX.US)$ NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024 Tuesday, 17th December at 4:15 pm • Participants can register here for the virtual event airing 9:00am ET / 3:00pm CET PARIS and CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches t...
$Nanobiotix (NBTX.US)$ Nanotix on the volume. Apparently, the market doesn't recognize this ticker. It must be for college frat boys once they get done with class after hours.
NOTE: There are a lot on my watchlist today which did not yet run. Please do include them in your watchlist up to next week because there are delayed market reactions to news overshadowed by runners. $Chimerix(Delisted) (CMRX.US)$PR 12/9 after hours To Submit Dordaviprone For Accelerated Approval To U.S. FDA For Patients With Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End. Ran 100%+ but this is after hour news with conference call tomorrow at 8:30AM ET. May co...
Jaguar8
OPmichael_11
:
Yes mostly because it increases EPS, less dilution risk, and gives more value to shareholders and attractive to investors. Drawback is it has higher volatility and lesser liquidity
$Nanobiotix (NBTX.US)$ NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer Nanobiotix announced completion of Phase 1 study evaluating RT-activated NBTXR3 in pancreatic cancer patients. The study showed encouraging results with 23 months median Overall Survivalfrom diagnosis in 22 patients with locally advanced or borderline resectable pancreatic cancer, compared to 19.2 months historical control at MD Anderson. The treatment was well-tolerated, and inv...
$Nanobiotix (NBTX.US)$ NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024 NANOBIOTIX (NASDAQ: NBTX), a late-clinical stage biotech company, will host a virtual KOL event on June 18, 2024, from 9:00-10:30AM EDT / 3:00-4:30PM CEST. The event will feature experts including Dr Colette Shen, Dr Ari Rosenberg, and Dr Jeffrey Bockman, who will discuss the company's lead product, NBTXR3. This product, whe...
1
Report
No comment yet
Sign in to post a comment
Market Insights
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Nanobiotix Stock Forum
Nanobiotix Reports Mixed 2024 Results: Extended Cash Runway vs Growing Losses
New Cancer Trial Breakthrough: NBTXR3 Delivers 83% One-Year Survival in Advanced Lung Cancer Patients
Breakthrough: Nanobiotix Reveals Dual Phase 1 Results for Novel Lung Cancer Therapy
Nanobiotix Lands Major J&J Deal Update: $2.6B Potential Value, Cash Through 2026
NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024
Tuesday, 17th December at 4:15 pm
• Participants can register here for the virtual event airing 9:00am ET / 3:00pm CET
PARIS and CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches t...
📊⚡️📊
$Chimerix(Delisted) (CMRX.US)$ PR 12/9 after hours To Submit Dordaviprone For Accelerated Approval To U.S. FDA For Patients With Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End. Ran 100%+ but this is after hour news with conference call tomorrow at 8:30AM ET. May co...
NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer
Nanobiotix announced completion of Phase 1 study evaluating RT-activated NBTXR3 in pancreatic cancer patients.
The study showed encouraging results with 23 months median Overall Survivalfrom diagnosis in 22 patients with locally advanced or borderline resectable pancreatic cancer, compared to 19.2 months historical control at MD Anderson.
The treatment was well-tolerated, and inv...
NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024
NANOBIOTIX (NASDAQ: NBTX), a late-clinical stage biotech company, will host a virtual KOL event on June 18, 2024, from 9:00-10:30AM EDT / 3:00-4:30PM CEST. The event will feature experts including Dr Colette Shen, Dr Ari Rosenberg, and Dr Jeffrey Bockman, who will discuss the company's lead product, NBTXR3. This product, whe...
No comment yet